The effect of Agomalatin on resistant obsessive compulsive disorder patients

The comparison of the effect of Agomalatin and Placebo on symptoms of obsession in resistant obsessive compulsive disorder patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190726044339N3

Enrollment

Registered

2020-12-23

Start date

2020-11-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive-compulsive disorder (OCD). Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: agomelatin 25 mg one tablet per night with 100 mg of sertraline daily for 12 weeks. Intervention 2: Control group: One placebo tablet every night with a daily intak

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with resistant obsessive-compulsive disorder who have not taken any medication for 3 months before the start of the study Score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) above 15

Exclusion criteria

Exclusion criteria: Having other psychiatric disorder Pregnancy and lactation Having Hepatic disorder Receive concomitant psychotherapy

Design outcomes

Primary

Measure	Time frame
Obsession severity. Timepoint: At the beginning of the study and at the 12th week. Method of measurement: Yale-Brown Obsessive Compulsive Scale (Y-BOCS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Nejati

Shiraz University of Medical Sciences

hamdi_88114@yahoo.com+98 71 3228 9601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026